Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites
- PMID: 2699996
Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites
Abstract
Insulin resistance is almost universal among uremic patients. There are, however, two different subgroups of uremic patients with regard to glucose tolerance. About half of uremic patients can augment their insulin secretion in response to glucose loads to overcome the insulin resistance and maintain glucose tolerance. In the other half of uremic patients, insulin secretion following glucose loads is not different from normal values so that glucose intolerance results. There is recent evidence that hyperparathyroidism or vitamin D deficiency may inhibit insulin secretion in uremia. Parathyroid hormone (PTH) concentrations correlated inversely with glucose tolerance in adolescents with chronic renal insufficiency. Insulin hypersecretion in response to glucose loads occurred only in uremic patients with normal PTH concentrations. Surgical correction of hyperparathyroidism in uremic patients on hemodialysis led to the resolution of glucose intolerance with an increase in insulin secretion and no change in insulin resistance. However, the role of vitamin D repletion was not separately assessed since these patients were supplemented with vitamin D post-operatively. Medical correction of hyperparathyroidism by high-dose phosphate binders and vitamin D led to similar changes in glucose metabolism in children with chronic renal insufficiency. Glucose intolerance resolved, insulin secretion increased, and insulin resistance persisted. In the latter study, plasma 1,25-dihydroxycholecalciferol (DHCC) increased significantly following phosphate restriction. Recently, a preliminary study showed that intravenous 1,25-DHCC acutely restored glucose tolerance and increased insulin secretion in uremic patients on hemodialysis without simultaneous changes in serum PTH, ionized calcium, phosphate, magnesium or potassium concentrations. Thus, 1,25-DHCC, independently of PTH and calcium, may be important in the control of insulin secretion in uremic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Effects of parathyroid hormone infusion on glucose tolerance and glucose-stimulated insulin secretion in normal and uremic rats.Diabetes Res Clin Pract. 1998 Aug;41(2):85-94. doi: 10.1016/s0168-8227(98)00067-9. Diabetes Res Clin Pract. 1998. PMID: 9789714
-
[Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].Klin Wochenschr. 1979 Oct 1;57(19):1053-9. doi: 10.1007/BF01479991. Klin Wochenschr. 1979. PMID: 392179 Review. German.
-
[Clinical significance and pathogenic mechanisms of insulin resistance in chronic renal insufficiency (part II): pathogenic factors of insulin resistance in chronic renal insufficiency].Med Pregl. 2000 Mar-Apr;53(3-4):159-63. Med Pregl. 2000. PMID: 10965681 Review. Croatian.
-
Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients.Kidney Int. 1992 Apr;41(4):1049-54. doi: 10.1038/ki.1992.159. Kidney Int. 1992. PMID: 1513086 Clinical Trial.
Cited by
-
A new paradigm for the treatment of secondary hyperparathyroidism.NDT Plus. 2008 Jan;1(Suppl 1):i24-i28. doi: 10.1093/ndtplus/sfm041. NDT Plus. 2008. PMID: 25983953 Free PMC article.
-
Derangement of glucose metabolism in hyperparathyroidism.J Endocrinol Invest. 2003 Nov;26(11):1136-42. doi: 10.1007/BF03345264. J Endocrinol Invest. 2003. PMID: 15008255 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical